Ozempic Lawsuit – April 2025 Update

Individuals are filing Ozempic lawsuits against Novo Nordisk because of gastroparesis and other gastrointestinal injuries. These lawsuits have been consolidated into MDL No. 3094 – In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation in the Eastern District of Pennsylvania. As of November 2024, there are 1,221 lawsuits pending in the federal multidistrict litigation. The presiding judge is Karen Spencer Marston. This lawsuit is in the early stages, with case management deadlines currently being set. People are continuing to file Ozempic lawsuits today. 

Ozempic Lawsuit Timeline & News – April 2025

+

What is the Ozempic Lawsuit About?

Concerns over the safety of Ozempic continue as patients report more adverse health events, including severe gastrointestinal issues, blood clots, and vision loss that severely impacts a person’s quality of life. Many lawsuits center around Ozempic patients who have suffered gastroparesis, a serious condition involving the paralysis of the stomach and intestinal blockages. Symptoms of these conditions include the inability to eat and persistent vomiting or diarrhea. Plaintiffs argue that the manufacturer of Ozempic, Novo Nordisk, failed to warn consumers about potential harm when taking the injection.

Ozempic Lawsuit Information
Lawsuit Name:	MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Main Injuries:	Gastroparesis, pancreatitis, gallbladder inflammation, gallstones, vomiting, diarrhea, NAION (vision loss), and intestinal obstruction (ileus)
Defendants:	Novo Nordisk: Ozempic, Wegovy, Rybelsus, and Saxenda)
Mass tort or class action?	Mass tort
MDL Number:	3094
Pending Cases:	1,221
Court Name (Venue):	Eastern District of Pennsylvania
Have There Been Settlements?	No
Active Lawsuit?	Yes

Why Are People Filing Ozempic Lawsuits?

Lawsuits against Novo Nordisk, the manufacturer of Ozempic, allege the pharmaceutical giant knew or should have known the drug carried a significant risk of harm for users. Legal documents indicate Ozempic patients have suffered serious injuries after taking the injectable prescription medication, including gastroparesis (stomach paralysis),  ileus (intestinal blockage), blood clots, and vision loss. These injuries have the potential for long-term health problems that profoundly affect a person’s quality of life. Aggrieved individuals report missing work, incurring hefty medical bills, and an impact on their overall well-being and relationships. 

It is further alleged the manufacturer put profits over patients as they received reports of adverse events related to the use of Ozempic but failed to update labeling or recall the medication. 

Our legal partners are currently investigating Ozempic lawsuits involving a diagnosis of:

Ozempic Lawsuits Spotlight

First Filed Lawsuit: RODERICK SHIRLEY vs. NOVO NORDISK et al.

In December 2023, Roderick Shirley, through his attorneys, filed a complaint against Novo Nordisk in the Eastern District of Pennsylvania. His lawsuit alleges the company engaged in negligence, misleading marketing, failure to warn, and consistently downplayed the risks associated with the drug. Mr. Shirley, an 82-year-old man, was prescribed Ozempic in 2022. While taking the medication, he suffered severe pain, which was related to a blood clot called a DVT). The DVT caused a pulmonary embolism, which necessitated life-saving treatment, deeply impacting his quality of life. His lawsuit alleges that Ozempic caused the DVT and other injuries. 

Filed Lawsuit: CECILY KING V. NOVO NORDISK A/S, NOVO NORDISK INC. and ELI LILLY AND COMPANY

In August 2024, Cecily King, through her attorneys, filed a lawsuit against Novo Nordisk and Eli Lilly after suffering severe personal injuries related to her use of Ozempic and Trulicity. Ms. King took the medications from September 2021 until March 2024. She alleges the GLP-1 receptor agonist drugs caused her to sustain gastroparesis, a serious gastrointestinal condition marked by persistent vomiting, diarrhea, and abdominal pain. The lawsuit accuses the manufacturers of failing to adequately warn consumers about the risks associated with the drugs, fraudulent concealment, and negligent misrepresentation. 

Whom Are People Filing Ozempic Lawsuits Against?

Ozempic patients nationwide are filing lawsuits against Novo Nordisk, a Danish pharmaceutical company founded in 1923. Today, the company has plants around the world and focuses on treating chronic conditions, including diabetes, cardiovascular disease, and obesity. 

In December 2017, the U.S. FDA announced the approval of Novo Nordisk’s blockbuster type 2 diabetes treatment, semaglutide, sold under the brand name Ozempic. The once-weekly injectable took the world by storm after patients reported noticeable weight loss while taking the medication. 

In addition to Ozempic, Novo Nordisk also manufacturers Rybelsus, an oral semaglutide used to treat type 2 diabetes; Wegovy, a semaglutide used to aid with weight loss; and Saxenda, a liraglutide used for chronic weight management.

Lawsuits have also been filed against Eli Lilly, a pharmaceutical company based in the United States. Eli Lilly manufactures Mounjaro, a tirzepatide used to lower A1C, and Trulicity, a dulaglutide used to treat type 2 diabetes.

The defendant in the Ozempic lawsuit is:

• Novo Nordisk

Defendant Profile: Novo Nordisk

Novo Nordisk is a pharmaceutical company headquartered in Denmark. In December 2017, Novo Nordisk announced FDA approval for their semaglutide injection, Ozempic. Ozempic, a glucagon-like peptide 1 (GLP-1) receptor agonist, was approved to treat type 2 diabetes in adults. The drug and its successors have experienced unprecedented growth, leading Novo Nordisk to announce an investment of over $4 billion in U.S. manufacturing to keep up with demand.

Allegations Against Novo Nordisk

Complaints filed against the Danish pharmaceutical company include that they knew or should have known about the severe risk of harm associated with the use of the drug, including the increased likelihood that patients could suffer serious gastrointestinal issues, blood clots, and vision loss. Additional allegations include that the company failed to warn consumers and healthcare providers about the risks and used misleading advertising to downplay the risks while promoting its benefits. Plaintiffs also accuse the company of negligence, defective design, and putting profits over patients as they repeatedly ignored safety concerns and reports of adverse events. 

What Stage is the Ozempic Lawsuit In?

Currently, over 1,200 GLP-1 lawsuits have been consolidated into multidistrict litigation out of the Eastern District of Pennsylvania. The litigation remains in the discovery phase. During the discovery phase, both parties are able to gather and exchange information about the case, including evidence and potential witnesses that may be used at trial. 

Multidistrict litigation helps streamline the pretrial process in lawsuits with a similar cause of action against one or more defendants. The judge in the case decides what evidence will be permitted and any case management deadlines that may apply. In the Ozempic lawsuit, Judge Marston ordered a deadline for fact discovery on July 2, 2025, for certain critical issues in the case. Plaintiffs must serve expert reports on these issues by July 16, and defendants have until August 13, 2025.  

What Is Ozempic And How Does It Work?

Ozempic is a GLP-1 receptor agonist used to treat type 2 diabetes, along with diet and exercise. The drug, an injectable semaglutide, was first approved by the FDA in 2017. It has since become one of the most popular prescription drugs in the United States. In addition to being prescribed to help lower A1C in adults with type 2 diabetes, the medication is also used off-label for weight loss.

GLP-1 receptor agonists, like Ozempic, work by mimicking a hormone that helps your body release its own insulin, prevents the liver from excess glucose production, and slows the rate at which food leaves the stomach, allowing you to feel fuller longer.  

Ozempic Mechanism of Action

Ozempic is the brand name for an injectable semaglutide manufactured by Novo Nordisk. The prescription medication is a GLP-1 receptor agonist that mimics a naturally occurring hormone in the body. The drug works by activating the GLP-1 receptors in the gastrointestinal tract, pancreas, and brain. 

The activation of these receptors helps the body produce insulin as blood sugar rises. It also slows gastric emptying, allowing the body to feel fuller longer and reducing appetite and glucagon release. 

Side Effects of Ozempic

Ozempic has a number of potential side effects. While the label lists common side effects and the potential for significant harm, such as an increased risk of thyroid C-cell tumors, pancreatitis, ileus, and diabetic retinopathy.. The FDA has received reports of serious gastrointestinal issues related to Ozempic, yet the label only lists a possibility of severe gastric reactions, without listing specific types of reactions, other than ileus.. Legal documents indicate the weekly injectable may cause long-term health conditions, including gastroparesis, bowel blockage, and vision disturbances.

In many instances, a higher dose of Ozempic equated to an increased likelihood of an adverse reaction. For instance, 15.8% of people taking a 0.5 mg injection experienced nausea, compared to 20.3% of people taking a 1.0 mg injection in clinical trials. Nausea, vomiting, and diarrhea were most often reported during periods of dose escalation.

Common Side Effects of Ozempic (Common Adverse Reactions)

Serious Side Effects of Ozempic (Less-Common Adverse Reactions)

Serious Side Effects Associated with the Ozempic Lawsuit

According to documents filed against the manufacturer of Ozempic, Novo Nordisk, there are several side effects that were not listed or properly represented on the label. These side effects are now the subject of numerous lawsuits due to their profound impact on consumers who note that they were not adequately warned about the potential of this kind of harm. 

Serious Side Effects Associated with the Ozempic Lawsuit:

• Gastroparesis (stomach paralysis)
• Ileus (bowel blockage)
• Blindness (NAION) and vision problems 
• Blood clot conditions such as deep vein thrombosis (DVT) and pulmonary embolisms (PE)

Injuries Caused By Ozempic

For patients taking Ozempic, there may be serious, potentially life-altering injuries caused by the drug. Lawsuits filed against Novo Nordisk suggest that patients may experience persistent vomiting, diarrhea, and severe abdominal pain associated with gastroparesis and ileus. In some instances, these injuries require surgery to be repaired and may impact a person’s quality of life. 

Ozempic and Stomach Paralysis (Gastroparesis)

Research suggests that Ozempic and other GLP-1 receptor agonists may substantially increase a person’s risk of developing gastroparesis or stomach paralysis. It is believed that the drug’s mechanism of action, which slows the rate at which food is released from the stomach, may cause this serious and painful condition. 

Outcomes for Gastroparesis

Individuals experiencing gastroparesis may have nausea, vomiting, and severe abdominal pain. There is no cure for the condition, and there can be dangerous complications, such as dehydration, blood sugar changes, and life-threatening blockages. Gastroparesis can be treated with changes to diet and addressing the underlying cause of the condition, but in some cases, it may require the insertion of a feeding tube. People who experience gastro-paresis after taking Ozempic may or may not see their symptoms resolve if they stop taking the drug.

Ozempic and Bowel Blockages and Ileus

Another condition reported by Ozempic patients is intestinal or bowel blockage. Referred to as ileus, the condition occurs when the muscles are unable to move food through the intestines, resulting in a blockage. The blockage can become life-threatening and may need surgery to correct.

Outcomes for Bowel Blockages and Ileus

Symptoms of ileus include abdominal swelling, vomiting, constipation, and a reduced appetite. Prolonged obstruction to the bowels can cause infection or death of the tissue and may require surgery to repair. Patients with severe blockages may be unable to work or return to normal activities as a result of the condition. 

Ozempic and Blood Clots and DVT

Individuals are filing lawsuits against the manufacturer of Ozempi, alleging the drug increases a person’s risk of developing deep vein thrombosis. Deep vein thrombosis occurs when a blood clot is formed in a deep vein of the leg, arm, or pelvis. If the blood clot breaks off, it can travel to the lungs, resulting in a potentially life-threatening pulmonary embolism. 

Outcomes for Blood Clots and DVT

A deep vein thrombosis is generally characterized by swelling and pain in the area where the blood clot has formed, but it may be present without any symptoms. When a deep vein thrombosis is detected, a person may be put on blood thinners to help resolve the clot. However, surgical intervention may be necessary to remove the clot. If the clot has caused a pulmonary embolism, it may be fatal. Prompt intervention is critical. Individuals who develop blood clots are often at risk for developing more despite intervention to remove or resolve the clots. 

Ozempic and NAION

Recent findings suggest that Ozempic may put individuals at an increased risk for developing a rare but serious condition known as Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). NAION may cause sudden blindness in one eye. It is generally painless, but is usually irreversible. 

Outcomes for NAION

Vision loss associated with NAION is generally permanent. It is caused by a stroke of the optic nerve due to the reduction of blood flow. There is no known cure or medication to treat the condition. 

Studies Linking Ozempic and Severe Injuries

Multiple studies have been published linking Ozempic and other GLP-1 receptor agonists to severe injuries such as those reported by patients nationwide. These studies indicate an increased risk for serious, potentially life-altering conditions such as gastroparesis, blood clots, and vision loss associated with the use of the drug. While additional research is needed to fully understand the nexus between the drug and these adverse outcomes, these studies point to the substantial safety concerns that may have been overlooked by the manufacturer. 

Ozempic Use Linked to Adverse Gastrointestinal Events

Study Highlight: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

In October 2023, researchers at the University of British Columbia published findings in the Journal of the American Medical Association (JAMA), which found an increased risk of adverse gastrointestinal events associated with GLP-1 receptor agonists used for weight loss. Adverse gastrointestinal events included pancreatitis, bowel obstruction, and gastroparesis. Individuals taking a GLP-1 receptor agonist were 9.1 times more likely to experience pancreatitis, 4.2 times more likely to have a bowel obstruction, and 3.7 times more likely to have gastroparesis compared to patients taking another type of drug.

Overview: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Description of Study:	The study found that individuals taking a GLP-1 receptor agonist such as Ozempic were at an increased risk for developing adverse gastrointestinal events compared to those taking another type of drug.
Published In:	Journal of the American Medical Association
Study Authors	Mohit Sodhi, Ramin Rezaeianzadeh, Abbas Kezouh, Mahyar Etminan
# of Participants	613 patients on semaglutide, 4,144 on liraglutide, and 654 on bupropion-naltrexone
Findings	The study found that individuals taking a GLP-1 receptor agonist such as a semaglutide were 3.7 times more likely to experience gastroparesis.

Ozempic Use Linked to Vision Loss and NAION

Study Highlight: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

In July 2024, researchers at Mass Eye and Ear found a potential link between the use of semaglutide and an increased risk of developing NAOIN, a rare but serious condition. NAION, or nonarteritic anterior ischemic optic neuropathy, can cause irreversible vision loss. The matched cohort study of over 16,000 patients was published in JAMA Ophthalmology and found patients prescribed a semaglutide for the treatment of type 2 diabetes were 4 times more likely to develop the condition. Those prescribed the medication for the treatment of obesity were seven times more likely. The researchers note that further studies are needed to determine the causality between the drug and the increased incidence of NAION.

Overview: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Description of Study:	An observational study to investigate a potential link between semaglutide and an increased incidence of NAION.
Published In:	JAMA Ophthalmology
Study Authors	Jimena, Tatiana Hathaway, Madhura P. Shah, David B. Hathaway, et al.
# of Participants	16,827 patients
Findings	Patients prescribed a semaglutide for treatment of type 2 diabetes were more than 4 times more likely to develop NAION.

Ozempic Use Linked to Blood Clots and Deep Vein Thrombosis (DVT)

Study Highlight: Comprehensive analysis of the safety of semaglutide in

type 2 diabetes: a meta-analysis of the SUSTAIN and

PIONEER trials

A study published in the Endocrine Journal in June 2021 found that semaglutide users had a 266% increased risk of developing DVT. The meta-analysis of 21 trials (PIONEER and SUSTAIN) with 12,260 semaglutide users and 14,176 comparators was funded by the Shenzhen Key Medical Discipline Construction Fund. 

Overview: Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials
Description of Study:	The study sought to assess the risk of serious adverse events (SAEs) associated with the use of semaglutide in patients with type 2 diabetes.
Published In:	Endocrine Journal
Study Authors	Dao-Gen Yin, Liang-Liang Ding, Hai-Rong Zhou, Mei Qiu, and Xue-Yan Duan
# of Participants	12,260 semaglutide users and 14,176 comparators
Findings	Type 2 diabetes patients taking a semaglutide were at a 266% increased risk of developing deep vein thrombosis.

Statements from the FDA About Ozempic

• On October 2, 2024, the FDA issued a postmarket safety information statement about concerns with unapproved versions of GLP-1 receptor agonists used for weight loss. These compounded semaglutide drugs do not undergo FDA reviews for safety or effectiveness and may be prone to dosing errors that result in hospitalization.
• On December 3, 2023, the FDA warned consumers against using counterfeit Ozempic (semaglutide). At least five adverse events were reported from a lot of counterfeit medication. The regulatory agency seized thousands of units that had entered the market.

What Damages Can People Sue Ozempic Manufacturers For?

Individuals who experience an adverse health event after taking Ozempic, such as gastroparesis, vision loss, or blood clots, may be eligible for compensation. Successful claims against the manufacturer of Ozempic, Novo Nordisk may include compensation for economic and non-economic losses. This includes coverage of medical bills, lost wages, and pain and suffering. 

Damages in an Ozempic lawsuit may include compensation for:

• Past and Future Medical Bills: Individuals who require medical attention as a result of Ozempic use may qualify for compensation related to past medical bills and future treatment, including any surgeries needed to reverse the effects of the drug.
• Lost Wages and Loss of Future Earning Capacity: If the injury inhibited job performance or required time off of work for recovery, plaintiffs may receive compensation for lost wages and the loss of future earning capacity.
• Loss of Consortium: If the Ozempic-related injury deprived a spouse or other close relative of the benefits of the relationship, there may be a claim for loss of consortium.
• Diminished Quality of Life: In some instances, such as where surgical intervention is required to treat the injury or long-term side effects associated with using Ozempic, a person’s quality of life is diminished. Depending on the circumstances of the case, a person may claim damages related to loss of quality of life if they are unable to perform their normal daily activities. 
• Physical Pain and Emotional Distress (Pain and Suffering): In some cases, a person may be able to claim compensation related to pain and suffering. These damages are harder to quantify since they provide compensation for any physical discomfort related to the injury, such as persistent vomiting, permanent vision loss, and diminished mental health.
• Punitive Damages: In rare cases, punitive damages are awarded to a plaintiff. These damages are typically reserved for cases where the defendant, in this case, Novo Nordisk, was grossly negligent or reckless in their actions. 
• Wrongful Death: If a loved one died as a result of Ozempic use, a close relative may be able to file a wrongful death claim. Damages in a wrongful death lawsuit may help to cover funeral and burial costs, loss of future income, pain and suffering, and more.

Who Qualifies to File an Ozempic Lawsuit?

In order to file an Ozempic lawsuit, each person has to meet certain eligibility requirements. Our legal partners are focusing on the specific injuries listed below:

• Diagnosis of a qualifying injury including gastroparesis (stomach paralysis), ileus (bowel obstruction), NAION (vision loss), deep vein thrombosis, or pulmonary embolism. 
• Evidence of Ozempic use through a prescription history or verified medical records.  
• Proof of medical intervention such as hospitalization or emergency room visit. Eligible individuals may also qualify if they were referred to a specialist such as a gastroenterologist or ophthalmologist to treat an Ozempic-related condition. 

What Proof Do You Need to File an Ozempic Lawsuit?

In order to file an Ozempic lawsuit, you must provide evidence to substantiate your claim. Evidence may include medical records that document the use of Ozempic and indicate a diagnosis of a severe adverse reaction related to its use, employment records showing time missed from work as a result of your diagnosis, and proof of purchase of brand-named Ozempic or an authorized generic semaglutide.  

Evidence of Ozempic Use and Timeline of Use

• Proof of Purchase: To file a successful claim against Novo Nordisk, you must prove that you used brand-name Ozempic. Used injectables and a detailed prescription history or pharmacy records may establish proof of purchase.
  
• Timeline Verification: One-time use of Ozempic may not be enough to establish eligibility. Medical records can help establish the date that you were prescribed the medication and any adverse reactions reported to your healthcare provider during its use.

Evidence About Your Diagnosis and Treatments

• Proof of Diagnosis: Medical records can help to prove when you received a diagnosis of your Ozempic-related injury. Tests such as MRIs, CT scans, and labs may be critical to proving your diagnosis.
  
• Hospital Records: Maintaining detailed records of any hospitalizations or emergency room visits related to your injuries is important, as these may not be found in your regular medical history.
  
• Treatment History: Any record of treatment should be preserved to show the severity of the injury, including medications taken to alleviate symptoms or surgical interventions

Evidence Showing Your Losses

• Medical Bills: Any medical expenses and other out-of-pocket losses related to your injury may qualify for compensation.
  
• Employment Records: To prove lost wages or future income loss, you must provide pay stubs or other employment records. These can also help to show a diminished quality of life if you are unable to perform the job duties you were doing prior to your injury.
  
• Cost of Future Care and Treatment: Estimates or invoices related to the cost of future care and treatment should be kept to document potential losses. 

Testimony From You and Your Family

• Journals or Personal Account: Personal testimony can help to establish how your Ozempic-related injury impacted your life or resulted in pain and suffering. Keeping a detailed journal or account of your injury, diagnosis, and treatment may prove essential.
  
• Statements from Families and Friends: Witness testimony may also help to bolster your claim. This includes statements from friends, family members, and coworkers who personally witnessed how the injury affected your life. 

Steps to File an Ozempic Lawsuit

There are several steps to file an Ozempic lawsuit. It is critical to consult with an experienced attorney as early in the process as possible to determine whether you meet the eligibility requirements necessary for a valid claim. An attorney will then assist in determining what evidence is necessary to prove your case and any legal requirements that may apply. 

These are the 8 steps for filing an Ozempic lawsuit:

1. Consult with an Experienced Attorney: First, it is crucial to consult with an attorney knowledgeable in Ozempic litigation and pharmaceutical mass torts. The attorney will provide a free case review to determine whether you meet the eligibility requirements necessary to file a claim.
   
2. Gather Evidence Related to Your Case: With the help of your legal team, you will need to gather evidence related to your case. The evidence necessary to support your case may include Ozempic prescription records, diagnosis of a qualifying injury such as gastroparesis, NAION, intestinal blockage, or DVT, and proof of damages.
   
3. Determine Applicable Legal Requirements: Due to the complexities of Ozempic litigation, it is essential to have a skilled attorney review your case to ensure it falls within the statute of limitations. Statutes of limitations are state-specific and may be affected by the date your injury was discovered.
   
4. File the Claim in Court: Once legal grounds are established, such as Novo Nordisk’s failure to warn consumers about the risks associated with the use of Ozempic, a lawsuit can be filed in the appropriate courthouse. An attorney will construct the complaint and ensure that all legal requirements are met prior to filing. Your case may be added to an existing lawsuit, such as the multidistrict litigation currently pending out of the Eastern District of Pennsylvania.
   
5. Engage in Discovery: Once the claim is filed, the case enters the Discovery phase. During this phase, each side is able to gather and exchange information related to the claim. The discovery phase helps to ensure that both parties are prepared for what will be presented at trial.
   
6. Enter into Negotiations: Throughout the process, your attorney may enter into negotiations with Novo Nordisk. A settlement can be reached at any time prior to trial.
   
7. Set the Matter for Trial:  If a favorable settlement cannot be reached, the matter may be set for trial. During the trial, both sides will present their case through evidence and witness testimony.
   
8. Resolve the Case: Depending on the outcome of the case, you may receive compensation related to your provable damages, or the matter may be eligible for appeal. 

What to Expect When Filing an Ozempic Lawsuit

It may take months to a year or more to resolve an Ozempic lawsuit. While there is no average timeline for these types of cases, negotiating and accepting a settlement may expedite the resolution of the case. 

Additionally, there is no set compensation in product liability claims against a pharmaceutical company like Novo Nordisk. Compensation typically varies based on the severity of the injury, the strength of the claim, and the outcome of each individual case. 

Attorneys generally handle Ozempic lawsuits on a contingency fee basis, meaning there are no upfront fees. Plaintiffs pay nothing unless money is recovered on their behalf.

What is the Deadline for Filing an Ozempic Lawsuit?

Ozempic lawsuits are governed by a statute of limitation or a legal deadline within which a claim must be filed. Statutes of limitations are state-specific and typically range from 1 to 6 years, although most are between 1 and 3 years, depending on the jurisdiction. The timeline usually begins from the date the injury occurred or was discovered; however, there are exceptions. 

Due to the complex nature of legal deadlines and the statute of limitations that may apply to your case, it is imperative to discuss your claim with an attorney as early in the process as possible. 

Statute of Limitations Rules and Exceptions:

• Discovery Rule: In most cases, the statute of limitations begins when the Ozempic-related injury was diagnosed or discovered. The date of discovery may be related to when the link between the drug and the condition was established. 
• Incapacitation or Minority: The statute of limitations may be extended if the person was incapacitated at the time of the injury or was a minor when the injury was discovered. 
• Wrongful Death Claims: The statute of limitations may differ in wrongful death claims but usually begins to toll from the date the person died. 

Early action is strongly recommended to ensure prompt filing of an Ozempic lawsuit. To ensure all legal deadlines are met, an attorney should be consulted as close to the date the injury is diagnosed or discovered as possible. Evidence should also be collected as soon as possible since it can take time to gather medical records and other documents necessary to prove your claim. 

Ozempic Settlements and Awards

Legal experts believe that Ozempic lawsuits may settle for between $400,000 and $700,000. Several factors may influence the potential settlement or jury award, including the severity of the injuries, prior case outcomes, the strength of the evidence, and the impact on the plaintiff’s quality of life. 

Average Settlement Amounts

While Ozempic lawsuits are still in the early stages, it is expected that settlements may range between $400,000 and $700,000, depending on the individual circumstances of the case. 

Factors Affecting the Value of an Ozempic Lawsuit

Several factors may influence the value of an Ozempic lawsuit. These factors may include the strength of the evidence, impact on the person’s quality of life, and whether the injury is life-altering. The ability to prove the severity of the injury is often the most critical in an Ozempic lawsuit settlement. 

Medical records showing the diagnosis and treatment of an injury resulting in permanent damage may result in higher compensation. Additionally, evidence that Novo Nordisk was grossly negligent or knowingly withheld safety information from consumers may result in punitive damages, increasing the potential compensation significantly. 

Learn More About Ozempic Lawsuits From Our Legal Team

Individuals who have suffered a serious injury after taking Ozempic, such as gastroparesis, intestinal blockage, vision loss, or blood clots, may be entitled to significant compensation. Ozempic lawsuits are pending across the country, with over 1,200 currently consolidated into an MDL out of the Eastern District of Pennsylvania. Failing to act now could result in your claim being denied. Consulting with an attorney well-versed in Ozempic litigation can help to ensure you receive the financial recovery you deserve.

FAQs